TVRD: תחזית צמיחת רווחים לשנה הבאה Cara Pharma

Cara Therapeutics Inc - לוגו גרפי של המנפיק TVRD

Cara Therapeutics Inc (TVRD) maintains a stable authority in the treatment of nephrogenic pruritus, supporting positive market expectations. An assessment of future earnings per share growth, based on the chart at GURU.Markets, shows that the indicator has settled at 25.00. This is a result of the company's commitment to the commercialization of innovative receptor agonists and the efficient use of external sterile drug manufacturing through strict SLA contracts.

TVRD - צמיחה צפויה ברווח נקי למניה בשנה הבאה Cara Therapeutics, Inc. בטווח 04.07.2022 - 18.11.2026

פילוחים אנליטיים ודוחות נתונים של חברת Cara Therapeutics, Inc. (TVRD)

הערכת שווי פונדמנטלית של החברה:Cara Corp, TVRD
מוצרים מוגמרים של Cara Therapeutics

This indicator calculates the percentage deviation of the expected net earnings per share for the following year from current values. It measures the market consensus regarding business scaling rates and capital management efficiency. Compliance with bioethical standards and the transparency of clinical trials at Cara Therapeutics Inc. (TVRD) mitigate regulatory risks, sustaining investment attractiveness. The trend in forward earnings per share growth forecasts determines the potential for the stock price.